SCCS Final Opinion on the Safety of Triclocarban and Triclosan
Ingredients: TRICLOCARBAN and TRICLOSAN

Date of publication: 25/10/2022

During the plenary meeting on 24-25 October 2022, the Scientific Committee on Consumer Safety (SCCS) presented its final opinion on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate

BACKGROUND

Triclocarban and Triclosan are ingredients used widely as preservatives in cosmetics and personal care products. They are both included in Annex V (list of preservatives allowed in cosmetic products) of the EU Cosmetics Regulation No. 1223/2009.

Triclocarban (CAS number: 101-20-2) can be used as a preservative up to a concentration of 0.2% in ready for use preparation, subject to purity criteria (Annex V, Entry 23). This ingredient is also included in the list of substances which cosmetic products must not contain except subject to the restrictions laid down (Annex III, Entry 100). For use other than as a preservative, Triclocarban may be used in rinse-off products up to a maximum concentration of 1.5%, subject to purity criteria. 

Triclosan (CAS number: 3380-34-5) may be used as a preservative in cosmetics up to a concentration of 0.2% in mouthwashes and up to 0.3% in other products like toothpastes, hand soaps, body soaps, deodorants (non-spray), face powders, etc. (Annex V, Entry 25).

Both Triclosan and Triclocarban have been assessed several times by the Scientific Committee on Consumer Safety (SCCS). These SCCS opinions resulted in the existing regulatory measures that allow different concentration of these ingredients based on the type of product and function.

In early 2019, a priority list of 28 potential endocrine disruptors (not already covered by the bans of cosmetic regulation) was established by the European Commission. From these 28 substances, 14 were considered as higher priority (Group A) and the other 14 were included in the low priority group (Group B).

The public call for data for the considered higher priority substances, including Triclocarban and Triclosan was carried out in 2019, with stakeholders submitting scientific evidence to demonstrate the safety of Triclocarban and Triclosan in cosmetic products. The European Commission requested the SCCS to carry out a safety assessment on these two substances considering the information provided (see previous post).

WHAT’S NEW?

During the plenary meeting on 24-25 October 2022, the SCCS presented its final scientific opinion on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products.

Based on all available information, including the potential endocrine effects of Triclocarban and Triclosan, the SCCS concluded that the use of Triclocarban as a preservative in dermally applied cosmetic products is safe up to a maximum concentration of 0.2% for both children and adults (0.5-18 years) and that this ingredient is also safe up to a maximum of 1.5% in rinse-off products for both children and adults (0.5-18 years) when used individually or in combination with a function other than preservative. However, the SCCS concluded that Triclocarban is not safe for adults and children in mouthwash, when used up to a maximum concentration of 0.2%, or in toothpaste for children below 6 years old.

According to the SCCS opinion, Triclosan is safe as a preservative when used individually or in combination up to a maximum concentration of 0.3% in toothpaste for both children and adults (0.5-18 years) but it is not safe when used in combination for children below 3 years old. Also, it is considered safe as a preservative in mouthwash at concentrations of 0.2% when used individually but not when used in combination, and not safe for children and adolescents at 0.2% even when used individually.

References:

1. Scientific Committee on Consumer Safety (SCCS). Scientific advice on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products. SCCS/1643/22 Final Scientific Advice

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »